Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | TPH1 | P17752 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527459 | 1.00 | GPR142 (0.43) | GPR142CYP17A1GRM2DPP4TPH1 | |
| SCHEMBL4526794 | 0.91 | TPH1 (0.39) | GPR142CYP17A1DPP4TPH1 | |
| SCHEMBL4517312 | 0.90 | GPR142 (0.43) | GPR142CYP17A1ROCK1 | |
| SCHEMBL4519177 | 0.89 | GPR142 (0.46) | GPR142CYP17A1DPP4TPH1ROCK1 | |
| SCHEMBL4533231 | 0.89 | GPR142 (0.38) | GPR142CYP17A1TPH1 | |
| SCHEMBL4524956 | 0.88 | ROCK1 (0.50) | GPR142CYP17A1DPP4CTSSCTSK | |
| SCHEMBL4523323 | 0.87 | GPR142 (0.45) | GPR142CYP17A1DPP4TPH1MMP2 | |
| SCHEMBL4516262 | 0.86 | MC4R (0.39) | GPR142CYP17A1DPP4MMP2ROCK1 | |
| SCHEMBL4512482 | 0.85 | CTSS (0.38) | CYP17A1DPP4CTSSCTSKROCK1 | |
| SCHEMBL4514247 | 0.81 | CIT (0.45) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | GPR142 3166/4885CYP17A1 3015/4885GRM2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.